Blue Goose Capital
Blue Goose Capital is a privately-held venture capital firm based in Sudbury, Massachusetts that makes Series A and Series B equity investments in US biotechnology companies, operating two fund vehicles (Blue Goose 1 and Blue Goose 2).
- Company typePrivate
- Founded-
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Blue Goose Capital does
Blue Goose Capital is a privately-held venture capital firm headquartered at 48 Plympton Rd, Sudbury, Massachusetts, specializing in equity investments in US biotechnology companies at the Series A stage and forward. The firm operates through two fund vehicles: the original Blue Goose 1 and the successor Blue Goose Capital 2 fund, which was announced in March 2024. Its disclosed investment focus spans antibody-drug conjugates, oncology resistance research, non-invasive blood cell monitoring, neurodegeneration therapeutics, respiratory digital health, vision technology, rehabilitation exoskeletons, DNA testing, and brain health — covering both therapeutics and medical device/digital health sub-sectors within biotech.
The firm generates returns through capital gains realized on portfolio company exits, IPOs, or secondary sales of equity. Deal sourcing is conducted via co-investor syndicates and direct network-based outreach rather than broad marketing. Blue Goose Capital does not develop proprietary technology products; its core product is capital allocation and sector expertise. Portfolio companies include Mythic Therapeutics (participated in $103M Series B), Therini Bio ($36M Series A), Aluna (~$19M Series B), and Leuko ($5M Series A), alongside other holdings such as WIVI Vision, ABLE, ADNTRO, AtG, and Newmanbrain. The firm maintains limited public-facing marketing and operates with a discreet, relationship-driven go-to-market motion.
The firm's value proposition rests on sector-specialized capital deployment in US biotech, providing growth capital to fund clinical advancement (including first-in-human studies), pipeline expansion, and regulatory milestones. Geographic scope is restricted to the United States. Ownership structure, fund size, team composition, and management fees are not publicly disclosed in available source material, constituting data gaps for deeper diligence.
Blue Goose Capital firmographics
Firmographics- Name
- Blue Goose Capital
- Legal name
- Blue Goose Capital
- Website
- https://bluegoosecap.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Blue Goose Capital is a privately-held venture capital firm based in Sudbury, Massachusetts that makes Series A and Series B equity investments in US biotechnology companies, operating two fund vehicles (Blue Goose 1 and Blue Goose 2).
- Ownership category
- akta.pro rank
Blue Goose Capital industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Blue Goose Capital is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Blue Goose Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Investment Returns / Capital Gains: Blue Goose Capital generates returns through equity investments in biotech startups. The fund makes Series A and Series B investments and realizes returns through exits, IPOs, or secondary sales of portfolio company equity.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Blue Goose Capital product offering
Product offeringCore offering
Blue Goose Capital is a venture capital firm that makes direct equity investments in US-based biotechnology companies at the Series A and Series B stages. The firm operates two fund vehicles (Blue Goose 1 and Blue Goose Capital 2, the latter announced in March 2024) and deploys specialized capital into startups developing novel therapeutics, medical devices, and digital health technologies. Returns are generated through exits, IPOs, or secondary sales of portfolio company equity.
Product overview
Blue Goose Capital is a venture capital firm focused on biotech investments in the US, operating two fund vehicles (Blue Goose 1 and Blue Goose 2). The firm does not appear to offer technology products or services; rather, it operates as an investment fund making Series A and forward-stage investments in biotechnology companies.
Differentiator
Problem solved
Functional benefit
Brands
- Blue Goose 1: First fund vehicle of Blue Goose Capital, focused on biotech investments
- Blue Goose 2
Products and services
- Blue Goose 1 Fund
- Blue Goose Capital 2 Fund
Companies that use Blue Goose Capital
Customer profileNamed customers8 records
Segments1 record
Ideal customer profiles1 record
Blue Goose Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Blue Goose Capital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- General OpticacoreWIVI Vision, a Blue Goose Capital portfolio company, entered into a partnership agreement with General Optica to include WIVI Vision's technology in several of their optical shops. This represents a go-to-market partnership for the portfolio company's technology distribution.
Scale indicators4 records
Recent moves6 records
Expansion highlights3 records
Blue Goose Capital competitors and assessment
Company assessmentDirect peers
- Section 32: Section 32 is a venture capital fund focused on biotech, techbio, and healthcare at early and growth stages. Directly comparable to Blue Goose given biotech specialization and early-stage Series A/B orientation.
- Flagship Pioneering: Flagship Pioneering creates and funds early-stage biotech platforms, with deep specialization in therapeutics and life sciences. Comparable to Blue Goose for sector focus but typically operates earlier at the company-creation stage.
- ARCH Venture Partners: ARCH Venture Partners invests in early-stage biotech and technology companies, often co-founding and seeding life sciences ventures. Comparable to Blue Goose for early-stage biotech focus and syndicate participation.
- OrbiMed Advisors: OrbiMed is a healthcare-dedicated investment firm managing funds across venture, growth, and credit in biotech and medtech. Comparable to Blue Goose for biotech focus but operates at a meaningfully larger AUM scale.
- Lux Capital: Lux Capital invests in science-driven and frontier-technology companies including biotech and life sciences at early stages. Comparable to Blue Goose for early-stage investing in science-heavy categories.
- Third Rock Ventures: Third Rock Ventures launches and invests in early-stage biotech companies focused on transformative therapies. Directly comparable to Blue Goose for biotech-only sector focus and company-building approach.
- 5AM Ventures: 5AM Ventures is an early-stage venture capital firm focused on life sciences and biotech, investing in Series A rounds. Comparable to Blue Goose in fund-stage focus and biotech sector specialization.
- Atlas Venture: Atlas Venture is a leading early-stage biotech-focused venture capital firm that builds and invests in therapeutic companies at the seed/Series A stage. Directly comparable to Blue Goose given its biotech specialization and early-stage investment focus.
- RA Capital Management: RA Capital is a healthcare and biotech-focused investment firm with dedicated early-stage life sciences strategies. Comparable to Blue Goose for its sector specialization and early-to-mid-stage biotech investment activity.
Broad incumbents
- Andreessen Horowitz (a16z Bio): a16z operates a dedicated bio/health fund alongside broad tech investing, providing a much larger platform than Blue Goose. Comparable as a sector-specialist investor in biotech but operates at significantly greater scale and brand.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Blue Goose Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Blue Goose Capital leadership team
Management profileNumber of profiles
Blue Goose Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Blue Goose Capital M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Blue Goose Capital
What does Blue Goose Capital do?
Blue Goose Capital is a venture capital firm that makes direct equity investments in US-based biotechnology companies at the Series A and Series B stages. The firm operates two fund vehicles (Blue Goose 1 and Blue Goose Capital 2, the latter announced in March 2024) and deploys specialized capital into startups developing novel therapeutics, medical devices, and digital health technologies. Returns are generated through exits, IPOs, or secondary sales of portfolio company equity.
Is Blue Goose Capital a public or private company?
Blue Goose Capital is a private company. It is classified as unknown and is currently operating.
When was Blue Goose Capital founded?
Blue Goose Capital was founded in -1. It employs 1 to 10 people.
Where is Blue Goose Capital based?
Blue Goose Capital is headquartered in Cambridge, United States, in the North America region.
How does Blue Goose Capital make money?
One revenue line is on record: investment Returns / Capital Gains.
Who are Blue Goose Capital's main competitors?
Direct peers on record are Section 32, Flagship Pioneering, ARCH Venture Partners, OrbiMed Advisors, Lux Capital, Third Rock Ventures, 5AM Ventures, Atlas Venture and RA Capital Management. Andreessen Horowitz (a16z Bio) is listed as a broad incumbent.
Does Blue Goose Capital have an API?
No public API is recorded for Blue Goose Capital.
What industry is Blue Goose Capital in?
Blue Goose Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.